Why conduct clinical trials in Australia..


We highly recommend for our clients to consider conducting clinical trials in Australia! Here are few facts...


High-quality research and facilities

Australia has a strong reputation for the quality of its scientific and medical research. Australia is internationally recognised for its highly trained clinical workforce and the high-quality, clean and accurate data produced by its experienced, trained (and accredited) research teams. Australian clinical research sites also have high-quality clinical facilities with state-of-the-art equipment for testing, treatment and analysis. These characteristics of the Australian environment ensure high quality research conduct and generate confidence in the findings of clinical trials conducted in Australia.

IAustralia adheres to the highest level of GCP standards, meaning that Australian clinical data and results are accepted by international regulatory agencies, including the US Food and Drug Administration and European Medicines Agency.

The Australian Therapeutic Goods Administration (TGA) has adopted the European Guideline CPMP/ICH/135/95 (and therefore the ICH E6 guidance) in principle, with some elements modified according to local regulatory requirements

Efficient ethics and regulatory framework

Australia has a fast and pragmatic regulatory pathway for clinical trials. Under the Clinical Trials Notification (CTN) scheme administered by the Therapeutic Goods Administrationhttp://www.australianclinicaltrials.gov.au/sites/all/modules/contributed/extlink/extlink.png) 100% 50% no-repeat;"> (TGA), research proposals are submitted directly to Australian human research ethics committees (HRECs) which assume the primary review responsibility for ethical and scientific review. The usual review cycle takes only 4 to 8 weeks and is based on the submission of a protocol, investigator brochure and if required, an independent toxicology report. This effective and efficient process avoids costly preparation of extensive regulatory applications and means that research can start much sooner.

The TGA also administers the Clinical Trials Exemption (CTX) scheme, under which proposals are submitted to the TGA for scientific review followed by ethical review conducted by the HREC.

Australia has recently developed ethics review processes for multi-centre research that help to reduce unnecessary duplication of review of research.

Diverse participant recruitment pool

Australia has an informed and willing population of potential trial participants, resulting in a higher level of research participation than would be expected from a population of our size. Australia is a multicultural country with a diverse population that is capable of meeting recruitment needs. Recent recommendations by the Clinical Trials Action Group, including the development of this website — www.australianclinicaltrials.gov.au — are helping to improve awareness and support patient recruitment.

The Australian Institute of Health and Welfare collects statistics on Australian risk factors, diseases and death in Australiahttp://www.australianclinicaltrials.gov.au/sites/all/modules/contributed/extlink/extlink.png) 100% 50% no-repeat;">, and provides links to online data collectionshttp://www.australianclinicaltrials.gov.au/sites/all/modules/contributed/extlink/extlink.png) 100% 50% no-repeat;">, providing useful information for sponsors considering placing trials in Australia.

Australian treatment processes and regimens are often very similar to the United States, Canada and western European countries. This enables recruitment of a patient population that is likely to mirror recruitment in those countries.

Investment incentives

he Australian Government’s generous new R&D Tax Incentive encourages more industry investment in research and development (R&D).

The Incentive provides businesses investing in eligible R&D with generous tax offsets:

  • a 45 per cent refundable R&D tax offset (equivalent to 45c per $1 of eligible R&D) for companies with aggregated annual turnover of less than A$20 million; and
  • a 40 per cent non-refundable R&D tax offset (equivalent to 40c per $1 of eligible R&D) for all other eligible companies.

Other benefits under the new R&D Tax Incentive include:

  • Clinical trials can be eligible R&D activities under the program and are considered for eligibility under the same rules as any other activity;
  • The Incentive provides for increased access by international companies. In particular, there is no requirement to hold the intellectual property in Australia;
  • Certainty and stability of the rate of support to companies as the rates are no longer linked to the company tax rate;
  • Increased level of expenditure that can be claimed on R&D activities undertaken overseas in support of Australian R&D projects, under certain conditions.

    Seasonal differences

    The fact that the Northern and Southern hemisphere seasons are reversed also provides an advantage when conducting trials in Australia that depend on seasonal factors, such as cooler weather, by allowing seasonal treatment trials (e.g. flu vaccine, allergy or respiratory ailments trials) to be conducted or continued in Australia during the northern hemisphere’s off-season.